Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | MAOA | P21397 | 2/20 | 0.70 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.70 |
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.54 |
| ▸ | PPARG | P37231 | 5/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.51 |
| ▸ | THRA | P10827 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9570630 | 0.87 | ALDH1A1 (0.67) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL9570559 | 0.83 | MAPT (0.83) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL22971780 | 0.83 | MAOA (1.00) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL1411677 | 0.82 | MAPT (0.71) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL8182157 | 0.79 | MAPT (0.62) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL22971778 | 0.79 | MAOA (1.00) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL290413 | 0.78 | MAPT (0.75) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL8182679 | 0.78 | PTPN1 (0.79) | ALDH1A1NPSR1MAOACISD1MAOB | |
| SCHEMBL13846702 | 0.77 | PPARG (0.59) | ALDH1A1NPSR1MAOACISD1MAOB | |
| Glitazone SCHEMBL623021 | 0.77 | MAPT (0.73) | ALDH1A1NPSR1MAOACISD1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4376777-A | Thiazolidine derivatives use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-03-15 | — | — | US | claimed |
| US-20120238750-A1 | AROMATIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2012-09-20 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8236826-B2 | Diarylether derivatives as antitumor agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-07 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8188277-B2 | Aromatic compounds for suppressing the generation of collagen | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
| US-20070270422-A1 | Aromatic Compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238750-A1 | AROMATIC COMPOUND | CBR1, CBR3, CYP1A1 | ALDH1A1 565/4885NPSR1 885/4885MAOA 624/4885 |
| US-20100004438-A1 | DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS | ROS1, CBR1, CBR3 | ALDH1A1 265/4885NPSR1 1788/4885MAOA 3148/4885 |
| US-20070270422-A1 | Aromatic Compounds | COL1A1, COL2A1, COL14A1 | ALDH1A1 475/4885NPSR1 1136/4885MAOA 317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.